1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
  1. Beenthere2Hippie
    A drug to treat alcohol problems was licensed for use in the UK despite insufficient evidence it was effective, researchers in Scotland have found. Nalmefene was approved for use in Europe in 2013 and then recommended by NICE (National Institute for Health and Care Excellence). But scientists at the University of Stirling found issues with the clinical trials and the way they were analysed.

    No-one from NICE was available for comment.

    The university said the way the trials had been conducted made it impossible to know how much the drug - marketed as Selincro - actually helped to reduce drinking in patients dependent on alcohol. Scientists analysed the published studies that formed the basis of the European licensing and the decision by NICE. They concluded the evidence of its effectiveness was "weak" and that any possible effect on patients was small - about a one drink per day reduction on average.

    Critical Questions

    The research, published in the journal Addiction, also found nalmefene was more expensive than similar drugs on the market and that no comparison with these alternatives was made. Dr Niamh Fitzgerald, a pharmacist and lecturer in alcohol studies at the university, said: "It's vitally important that we know that prescribed drugs are effective in treating the intended problem.

    "In this case, we found problems with the registration, design, analysis and reporting of these clinical trials which did not prevent the drug being licensed or recommended for use.

    "We believe this creates a difficulty for doctors trying to treat alcohol dependence and throws up critical questions for regulators around why a drug was licensed without a bank of high quality, reliable evidence."

    The drug is currently licensed to be used in conjunction with psychosocial support. It is intended to reduce alcohol consumption in patients diagnosed with alcohol dependence, with consistently high alcohol consumption levels, but who do not experience physical withdrawal symptoms when they stop drinking.

    BBC/June 6, 2016
    Newshawk Crew

    Author Bio

    BT2H is a retired news editor and writer from the NYC area who, for health reasons, retired to a southern US state early, and where BT2H continues to write and to post drug-related news to DF.


To make a comment simply sign up and become a member!